New Implant-Based System Gains FDA Approval for GERD Treatment

Gastroesophageal reflux disease is often treated surgically with techniques that encircle the esophagus, a strategy associated with dysphagia, inability to belch or vomit, and gas bloating. Clinicians continue to seek options that correct the anatomical cause of reflux while preserving normal function at the gastroesophageal junction. A new implant-based system has launched that restores the junction without compressing the food passageway. A newly approved device now offers a U.S. surgical option following Food and Drug Administration Premarket Approval.

Implantica AG’s RefluxStop has received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) as an implant-based treatment for gastroesophageal reflux disease (GERD), allowing the company to begin commercial launch activities in the United States. The decision follows a full review of the PMA application, including long-term clinical evidence supporting the therapy’s safety and effectiveness through five years.

RefluxStop is designed to address the underlying anatomical cause of acid reflux by restoring and maintaining the natural position of the gastroesophageal junction without encircling or placing pressure on the food passageway. Conventional anti-reflux procedures typically rely on wrapping or constricting the esophagus and can be associated with swallowing difficulties, inability to belch or vomit, and gas bloating. By keeping the lower esophageal sphincter in its normal anatomical position, the implant is intended to preserve physiological function while reducing reflux.

According to its approved indication, RefluxStop is a sterile implantable device intended to treat acid and non-acid reflux in patients diagnosed with GERD. The device maintains the gastroesophageal junction in a defined intra-abdominal position, allowing the lower esophageal sphincter to function naturally. Patient eligibility is determined by abnormal impedance pH and/or pH testing consistent with GERD and suitability for implantation using the dedicated deployment tool.

Five-year clinical outcomes for RefluxStop have been published in peer-reviewed journals. The company also reports that commercial experience across multiple centers supports the clinical trial findings and indicates that the device can treat GERD without wrapping or constricting the esophageal sphincter, potentially avoiding side effects associated with other surgical approaches. The FDA approval marks a major milestone for the program and clears the way for U.S. commercial launch preparations.

Related Links
Implantica